Patient-Derived Gastric Cancer Assembloids Reveal Stromal Impact

Study Background and Research Question

Gastric cancer remains a major clinical challenge due to its pronounced cellular heterogeneity and poor prognosis, with five-year survival rates below 10% for advanced disease. Traditional in vitro models, such as tumor organoids, have advanced preclinical research but fall short in replicating the complex tumor microenvironment (TME) that profoundly influences drug response and resistance. Notably, the diverse populations of cancer-associated fibroblasts and stromal cells contribute significantly to therapeutic outcomes and are implicated in the development of antifolate drug resistance, including resistance to agents like methotrexate. The key research question addressed by Shapira-Netanelov et al. (2025) is whether integrating matched stromal cell subpopulations with patient-derived tumor organoids can yield an assembloid model that more accurately reflects individual tumor biology and drug response landscapes.

Key Innovation from the Reference Study

The principal innovation in this work is the development of a patient-specific gastric cancer assembloid platform that incorporates both tumor epithelial cells and autologous stromal cell subtypes—each expanded in tailored growth media. This integration enables the recreation of cellular heterogeneity and TME features observed in primary tumors. Unlike conventional organoid cultures, the assembloid system supports the co-existence and functional interaction of multiple cell types, facilitating the investigation of cell–cell signaling, extracellular matrix remodeling, and inflammatory crosstalk. The model thus offers a more physiologically relevant system for drug screening and for uncovering mechanisms of treatment resistance that standard monocultures cannot reveal, as demonstrated in the reference study.

Methods and Experimental Design Insights

The experimental pipeline began with the dissociation of fresh gastric tumor tissue to isolate various cell populations. Tumor epithelial organoids were cultured in optimized media, while stromal cell subpopulations—including mesenchymal stem cells, fibroblasts, and endothelial cells—were isolated and expanded using lineage-specific conditions. These subpopulations, derived from the same patient tissue, were subsequently recombined in defined ratios to establish three-dimensional assembloids in an optimized co-culture medium.

Phenotypic and molecular characterization was performed using immunofluorescence microscopy to assess epithelial and stromal marker expression. Transcriptomic profiling by RNA sequencing provided insights into gene expression dynamics under different co-culture conditions. Drug responsiveness was evaluated via cell viability assays following treatment with a spectrum of therapeutics, enabling comparative analysis of drug effects in organoid-only versus assembloid settings.

Protocol Parameters

• Tumor dissociation and cell expansion: Fresh gastric tumor tissue is enzymatically and mechanically dissociated; epithelial organoids and stromal subtypes are expanded in lineage-specific media.
• Assembloid formation: Matched epithelial and stromal cells are recombined in optimized ratios within a three-dimensional matrix and maintained in a co-culture medium that supports all cell types.
• Molecular characterization: Use of immunofluorescence staining for lineage markers and RNA sequencing for transcriptomic profiling of assembloid versus monoculture conditions.
• Drug sensitivity assays: Application of chemotherapeutic agents and targeted therapies followed by cell viability and proliferation assays to evaluate treatment response and resistance patterns.

Core Findings and Why They Matter

Assembloids generated by this methodology exhibited cellular architecture and marker expression closely mirroring those of the original tumors. Notably, the presence of stromal subpopulations modulated the expression of inflammatory cytokines, extracellular matrix components, and tumor progression-associated genes. Drug screening revealed marked patient- and drug-specific heterogeneity in response profiles; certain agents effective in organoid-only models lost efficacy in assembloids, underlining the critical influence of stromal components on drug sensitivity and the emergence of resistance.

These findings underscore the limitations of monoculture models for predicting clinical responses and highlight the assembloid platform as a superior preclinical tool for investigating tumor–stroma interactions, dissecting resistance mechanisms (including those relevant to antifolate drugs), and guiding personalized therapy selection. For example, research on Leucovorin Calcium—a folate analog used to rescue cells from methotrexate-induced cytotoxicity—can benefit from such assembloid models, as they enable a more realistic assessment of protection from methotrexate-induced growth suppression within a complex TME.

Comparison with Existing Internal Articles

Several internal resources expand on the roles of calcium folinate (Leucovorin Calcium) in drug resistance and tumor model research. The article "Leucovorin Calcium: Advancing Drug Sensitivity Research" details how this compound serves as a rescue agent in antifolate chemotherapy studies, and discusses strategies for integrating Leucovorin Calcium into assembloid co-cultures to optimize drug response assays. Similarly, "Leucovorin Calcium: Folate Analog for Methotrexate Rescue" addresses its application in cell proliferation and viability assays relevant to antifolate drug resistance research. These resources complement the reference study by providing practical protocols and workflow guidance for incorporating Leucovorin Calcium into advanced preclinical models.

On the assembloid methodology itself, "Patient-Derived Gastric Cancer Assembloids Illuminate Stromal Impact" offers an accessible overview of how stromal integration enhances the predictive power of in vitro models, in alignment with the findings of Shapira-Netanelov et al. (2025).

Limitations and Transferability

Despite their improved physiological relevance, patient-derived assembloids present certain limitations. The complexity of isolating and expanding matched stromal subpopulations may not be feasible for all tumor types or clinical samples, and the approach requires advanced expertise in tissue processing and co-culture techniques. Additionally, while assembloids more closely approximate in vivo conditions than monocultures, they do not fully recapitulate immune cell dynamics, vascularization, or systemic pharmacokinetics. Transferability to high-throughput screening platforms or other cancer types warrants further validation. Caution should also be exercised in extrapolating findings to clinical outcomes, as in vivo confounders remain unmodeled.

Research Support Resources

To facilitate studies on drug sensitivity, antifolate resistance, and protection from methotrexate-induced growth suppression within assembloid or co-culture models, researchers may employ high-purity reagents such as Leucovorin Calcium (SKU A2489). This compound is widely used to modulate the folate metabolism pathway and rescue cells from methotrexate toxicity in cell proliferation assays, and its application is described in both the primary literature and related internal resources. For optimal storage, Leucovorin Calcium is recommended to be maintained at -20°C, with solutions prepared fresh for immediate use. APExBIO offers validated Leucovorin Calcium for research use, supporting advanced workflows in tumor microenvironment and antifolate drug resistance research.